Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303573 | 0.81 | CA2 (0.61) | CA12CA1CA2CA9 | |
| SCHEMBL1251842 | 0.78 | EPHX2 (0.49) | EPHX2NR1H4ENPP2PTGS2CA12 | |
| SCHEMBL4573368 | 0.76 | EPHX2 (0.47) | EPHX2NR1H4ENPP2PTGS2CA12 | |
| SCHEMBL1253851 | 0.76 | EPHX2 (0.47) | EPHX2NR1H4ENPP2GLAPTGS2 | |
| Hydrochloric Acid SCHEMBL1287377 | 0.76 | KDM4E (0.50) | EPHX2NR1H4ENPP2PTGS2CA12 | |
| SCHEMBL515532 | 0.75 | SMN1; SMN2 (0.46) | CA12CA1CA2CA9 | |
| SCHEMBL4633460 | 0.75 | LMNA (0.47) | CA2 | |
| SCHEMBL14508573 | 0.74 | EPHX2 (0.46) | EPHX2NR1H4ENPP2CA12CA1 | |
| SCHEMBL6594740 | 0.74 | ENPP2 (0.46) | EPHX2NR1H4ENPP2KCNJ1KCNH2 | |
| SCHEMBL21165326 | 0.73 | CA2 (0.66) | GLAPTGS2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919874-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (KY) | 2021-02-16 | — | — | US | disclosed |
| US-20190382370-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2019-12-19 | — | — | US | disclosed |
| US-10370354-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (KY) | 2019-08-06 | — | — | US | disclosed |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2018-08-09 | — | — | US | disclosed |
| EP-3351541-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9938255-B2 | Metalloenzyme inhibitor compounds | VPS-3, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2788343-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (NC) INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160214959-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2016-07-28 | — | — | US | disclosed |
| US-9309273-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2013090210-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | SHIONOGI & CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2128134-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | Shionogi&Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-2042502-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-1544199-B1 | NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20080161311-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2008-07-03 | — | — | US | disclosed |
| US-7211572-B2 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-20060052361-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1544199-A1 | NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | EPHX2 2979/4885NR1H4 3591/4885ENPP2 4574/4885 |
| US-20190382370-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GAA, GPX1 | EPHX2 1133/4885NR1H4 985/4885ENPP2 227/4885 |
| US-10919874-B2 | Metalloenzyme inhibitor compounds | MMEL1, GAA, GPX1 | EPHX2 1133/4885NR1H4 985/4885ENPP2 227/4885 |
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | MMP13, MMP3, MMP26 | EPHX2 3735/4885NR1H4 3910/4885ENPP2 1349/4885 |
| US-20060052361-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | EPHX2 2979/4885NR1H4 3591/4885ENPP2 4574/4885 |
| US-20080161311-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | DNTT, PNP, NNMT | EPHX2 3317/4885NR1H4 3963/4885ENPP2 4503/4885 |
| US-10370354-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | EPHX2 1202/4885NR1H4 1110/4885ENPP2 221/4885 |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | EPHX2 1202/4885NR1H4 1110/4885ENPP2 221/4885 |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | EPHX2 1202/4885NR1H4 1110/4885ENPP2 221/4885 |
| US-20160214959-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | EPHX2 1202/4885NR1H4 1110/4885ENPP2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.